BLACK DIAMOND THERAPEUTICS, INC. [●] Shares of Common Stock Underwriting AgreementBlack Diamond Therapeutics, Inc. • January 21st, 2020 • Biological products, (no disgnostic substances) • New York
Company FiledJanuary 21st, 2020 Industry JurisdictionBlack Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $ [●] per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.